169 related articles for article (PubMed ID: 36319631)
1. USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.
Huang WY; Liao ZB; Zhang JC; Zhang X; Zhang HW; Liang HF; Zhang ZY; Yang T; Yu J; Dong KS
Cell Death Dis; 2022 Nov; 13(11):917. PubMed ID: 36319631
[TBL] [Abstract][Full Text] [Related]
2. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
3. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
4. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
5. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
[TBL] [Abstract][Full Text] [Related]
6. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway.
Wang C; Zhang L; Cao M; Fu Z; Wang H; Zhang S; Zhu K; Hou Z; Cui J; Yue P; Guo H; Zhang T
FASEB J; 2023 Jun; 37(6):e22943. PubMed ID: 37104068
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
10. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
11. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
12. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
14. TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma.
Fu B; Meng W; Zeng X; Zhao H; Liu W; Zhang T
Biomed Res Int; 2017; 2017():4698167. PubMed ID: 28536696
[TBL] [Abstract][Full Text] [Related]
15. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
16. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
Li W; Fu Q; Man W; Guo H; Yang P
Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
18. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
19. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
20. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]